Alpine Immune Sciences, Inc. (ALPN): Price and Financial Metrics


Alpine Immune Sciences, Inc. (ALPN): $11.00

0.64 (+6.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALPN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

ALPN POWR Grades


  • ALPN scores best on the Growth dimension, with a Growth rank ahead of 77.01% of US stocks.
  • The strongest trend for ALPN is in Momentum, which has been heading down over the past 48 weeks.
  • ALPN ranks lowest in Momentum; there it ranks in the 5th percentile.

ALPN Stock Summary

  • Of note is the ratio of Alpine Immune Sciences Inc's sales and general administrative expense to its total operating expenses; merely 11.15% of US stocks have a lower such ratio.
  • As for revenue growth, note that ALPN's revenue has grown 508.16% over the past 12 months; that beats the revenue growth of 98.35% of US companies in our set.
  • Alpine Immune Sciences Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -22.2%, greater than the shareholder yield of only 12.21% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Alpine Immune Sciences Inc, a group of peers worth examining would be FULC, DTIL, ANAB, CARA, and CNCE.
  • ALPN's SEC filings can be seen here. And to visit Alpine Immune Sciences Inc's official web site, go to www.alpineimmunesciences.com.

ALPN Valuation Summary

  • ALPN's price/sales ratio is 12.7; this is 11.89% higher than that of the median Healthcare stock.
  • ALPN's price/sales ratio has moved NA NA over the prior 76 months.
  • Over the past 76 months, ALPN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ALPN.

Stock Date P/S P/B P/E EV/EBIT
ALPN 2021-08-31 12.7 5.2 -6.7 -7.0
ALPN 2021-08-30 12.3 5.1 -6.5 -6.8
ALPN 2021-08-27 12.7 5.2 -6.7 -7.0
ALPN 2021-08-26 12.3 5.1 -6.5 -6.8
ALPN 2021-08-25 12.6 5.2 -6.6 -6.9
ALPN 2021-08-24 12.3 5.0 -6.4 -6.7

ALPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ALPN has a Quality Grade of C, ranking ahead of 67.44% of graded US stocks.
  • ALPN's asset turnover comes in at 0.122 -- ranking 249th of 677 Pharmaceutical Products stocks.
  • ALNY, SELB, and TXMD are the stocks whose asset turnover ratios are most correlated with ALPN.

The table below shows ALPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.122 1 -0.458
2021-03-31 0.086 1 -0.661
2020-12-31 0.083 1 -0.777
2020-09-30 0.051 1 -1.140
2020-06-30 0.044 1 -0.895
2020-03-31 0.047 1 -0.716

ALPN Price Target

For more insight on analysts targets of ALPN, see our ALPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.3 (Strong Buy)

ALPN Stock Price Chart Interactive Chart >

Price chart for ALPN

ALPN Price/Volume Stats

Current price $11.00 52-week high $16.37
Prev. close $10.36 52-week low $7.21
Day low $10.51 Volume 285,400
Day high $11.66 Avg. volume 119,001
50-day MA $9.25 Dividend yield N/A
200-day MA $11.06 Market Cap 263.07M

Alpine Immune Sciences, Inc. (ALPN) Company Bio


Alpine Immune Sciences, Inc. is focused on developing novel protein‐based immunotherapies using its proprietary Variant Ig Domain vIgD platform technology. The vIgD platform is designed to interact with multiple targets, including many present in the immune synapse. Alpine’s vIgDs are developed using a process known as directed evolution, which can potentially produce proteins capable of either enhancing or diminishing an immune response and thereby may potentially apply therapeutically to both oncology and inflammatory diseases. The company formed following a July, 2017 merger with Nivalis Therapeutics.


ALPN Latest News Stream


Event/Time News Detail
Loading, please wait...

ALPN Latest Social Stream


Loading social stream, please wait...

View Full ALPN Social Stream

Latest ALPN News From Around the Web

Below are the latest news stories about Alpine Immune Sciences Inc that investors may wish to consider to help them evaluate ALPN as an investment opportunity.

3 Stocks Insiders Are Buying

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Sensient Technologies Th

Yahoo | September 24, 2021

32 Stocks Moving In Wednesday's Mid-Day Session

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share agreement with Google LLC to develop its enterprise tech platform and software products. Aethlon Medical, Inc. (NASDAQ: AEMD) jumped 49.1% to $5.67 on above-average volume. WiMi Hologram Cloud Inc. (NASDAQ: WIMI) gained 30.3% to $4.60 as the company reported revenue growth of 202.2% year-on-year to $79.9 million for the six month

Yahoo | September 22, 2021

20 Stocks Moving in Wednesday's Pre-Market Session

Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 70.1% to $9.68 in pre-market trading following an announcement from management that the company entered into a revenue share agreement with Google LLC to develop its enterprise tech platform and software products. Predictive Oncology Inc. (NASDAQ: POAI) rose 25.7% to $1.22 in pre-market trading. Alpine Immune Sciences, Inc. (NASDAQ: ALPN) rose 18.3% to $11.60 in pre-market trading. Alpine Immune Sciences recently announced a $91 million pri

Yahoo | September 22, 2021

Alpine Immune Sciences Announces $91 Million Private Placement

Alpine Immune Sciences, Inc. (NASDAQ: ALPN ), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced it has entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, as described below, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately $91 million, before deducting offering expenses. The private placement is being led by Frazier Life Sciences Public Fund with participation from Decheng Capital, BVF Partners, TCG X, Avidity Partners, OrbiMed, Omega Fund, and Logos Capital, among others. "As a long-term backer of Alpine, we are impressed by the company''s progress...

Benzinga | September 15, 2021

Alpine Immune Sciences Announces Participation in September Investor Conferences

SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences Announces Participation in September Investor Conferences

Business Wire | September 7, 2021

Read More 'ALPN' Stories Here

ALPN Price Returns

1-mo 15.79%
3-mo 22.22%
6-mo 2.04%
1-year 29.72%
3-year 73.78%
5-year -66.50%
YTD -12.70%
2020 228.13%
2019 4.35%
2018 -67.14%
2017 25.00%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9868 seconds.